Although the prevalence of anti-Ku antibodies is not homogenous, depending on several features such as disease type, genetic and geographical clustering, and also method of detection, they could be found in 55 % overlap PM/systemic sclerosis patients.
Moreover, anti-Ku antibodies are not associated with a particular clinical outcome, and especially with cancer related to myositis.